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The lack of efficient animal models for bipolar disorder (BPD), especially for the manic pole, is 
a major factor hindering the research of its pathophysiology and the development of improved 
drug treatments. The present study was designed to identify an appropriate mouse strain for 
modeling some behavioral domains of mania and to evaluate the effects of drugs using this 
strain. The study compared the behavior of four strains: Black Swiss, C57Bl/6, CBA/J and A/J 
mice in a battery of tests that included spontaneous activity; sweet solution preference; light/
dark box; resident-intruder; forced-swim and amphetamine-induced hyperactivity. Based on 
the ‘manic-like’ behavior demonstrated by the Black Swiss strain, the study evaluated the 
effects of the mood stabilizers valproate and lithium and of the antidepressant imipramine 
in the same tests using this strain. Results indicated that lithium and valproate attenuate the 
‘manic-like’ behavior of Black Swiss mice whereas imipramine had no effects. These findings 
suggest that Black Swiss mice might be a good choice for modeling several domains of mania 
and distinguishing the effects of drugs on these specific domains. However, the relevance of 
the behavioral phenotype of Black Swiss mice to the biology of BPD is unknown at this time 
and future studies will investigate molecular differences between Black Swiss mice and other 
strains and asess the interaction between strain and mood stabilizing treatment.
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Malkesman et al., 2009). This approach was the conceptual basis 
for the development of strains with direct mutations to be used 
as models for mania (Ralph-Williams et al., 2003; Roybal et al., 
2007). However, the identification of appropriate standard mice 
strains was also found productive. For example, strain variations 
in the effects of amphetamine and lithium suggest that only a few 
strains are suitable for use in the amphetamine-induced hyper-
activity model of mania (Gould et al., 2007). Preliminary experi-
ments in our laboratory suggest that based on their behavioral 
repertoire, mice from the Black Swiss (BS) strain may be more 
suitable for use in modeling a number of the domains of mania 
compared with other strains. Specifically, BS mice were found to 
demonstrate ‘manic-like’ increased risk-taking and reward-seeking 
behaviors as well as an elevated response to psychostimulants com-
pared with C57Bl/6 mice (Hiscock et al., 2007; Flaisher-Grinberg 
and Einat, 2009a).
The present study was designed to continue and explore the 
utility of the BS strain for modeling domains of mania. In Stage 
1, the behavior of BS mice was assessed in a continuous battery of 
tests relevant to the manic pole of BPD, including spontaneous 
activity, sweet solution preference, light/dark box, forced swim test 
(FST), resident-intruder and amphetamine-induced hyperactivity. 
These tests are part of a broader battery of tests that was suggested 
to model separate domains of mania (Einat, 2006). From this pro-
posed battery we chose to utilize the tests that have better valida-
tion in the context of affective disorders (for elaborated details, see 
Flaisher-Grinberg and Einat, 2009a). In Stage 2, in order to test the 
pharmacological (predictive) validity of the battery, the effects of 
IntroductIon
Bipolar disorder (BPD) is a chronic and debilitating illness which 
includes alternate episodes of depression and mania (Sadock and 
Kaplan, 2002). The estimated lifetime prevalence rate of BPD is 
3.9% and the median age of onset is 25 years. It is currently rec-
ognized that treatment outcomes for many bipolar patients are 
relatively poor, as significant side effects, high rates of relapse and 
lingering residual symptoms are evident (for review, see Miklowitz 
and Johnson, 2006).
The paucity of appropriate animal models for BPD hinders 
the research of the pathophysiology and the development of new 
treatments for this condition (Tecott and Nestler, 2004; Gould and 
Einat, 2007). A number of possible approaches for the development 
of new models for BPD and for mania include models based on 
molecular or genetic manipulations [e.g., Ralph-Williams et al., 
2003; Machado-Vieira et al., 2004; Einat and Manji, 2006; Roybal 
et al., 2007; Malkesman et al., 2009), models based on pharma-
cological interventions (Antelman et al., 1998; Gould et al., 2007; 
Riegel et al., 2009)] and models induced by environmental stressors 
[e.g., sleep deprivation (Gessa et al., 1995), dominant–submissive 
behavior (Knapp et al., 2002; Malatynska and Knapp, 2005), swim 
stress (Flaisher-Grinberg and Einat, 2009b)].
An additional possible approach emphasizes the identification 
or development of model animals (Insel, 2007). A model animal 
can be a specific species or a strain (either standard or with targeted 
mutation) which demonstrates behavioral or biological similarities 
with a disorder and may therefore be more homologous with it 
(Insel, 2007; Ashkenazy et al., 2008; Flaisher-Grinberg et al., 2008; Frontiers in Psychiatry  |  Psychopharmacology    April 2010  | Volume 1  | Article 10  |  2
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(Hiscock et al., 2007; Flaisher-Grinberg and Einat, 2009b; Flaisher-
Grinberg et al., 2009). Schedule of administration was selected based 
on previous work demonstrating its efficacy in some of the models 
included in the current study (Hiscock et al., 2007; Flaisher-Grinberg 
and Einat, 2009b; Flaisher-Grinberg et al., 2009).
EquIpmEnt and procEdurEs
Sequence of experiments
To minimize the effects of previous tests on later ones in the battery 
the order of tests was arranged from the less to the more intrusive 
(McQuade et al., 2003). In Stage 1, one cohort of mice was subjected 
to two sets of tests separated by 1 week of rest: spontaneous activity 
test; light/dark box; forced swim test; amphetamine-induced hyper-
activity (set 1) and sweet solution preference and resident-intruder 
tests (set 2). Specific tests were separated by 48-h rest period. In 
Stage 2, one cohort of mice was subjected to all six tests conducted 
on consecutive days in the following sequence: spontaneous activity 
test; sweet solution preference; light/dark box; resident-intruder 
test; forced swim test and amphetamine-induced hyperactivity test. 
The unification of the two test sets to one and the switch from 48 
to 24 h separation between tests followed a number of pilot tests 
which indicated no difference in the behavioral response of BS mice 
under these two conditions (data not shown).
Behavioral tests
Spontaneous activity. Mice were tested for spontaneous activity in 
50 × 25 × 20 cm transparent plastic automated activity monitors 
(Opto3, Columbus Instruments, Columbus, OH, USA). Infrared 
beam crossings were recorded for 60 min in 10-min intervals and 
total ambulatory activity was calculated across the entire session. 
At the end of the session mice were returned to their home cages 
and the boxes were wiped clean with a 10% alcohol solution.
Sweet solution preference test. Mice were supplied with a bottle 
of 1% saccharin solution (SIGMA, St. Lewis, MI, USA) on top of 
the regular supply of water and food. Saccharin concentration 
was selected as it is in the high end of the concentration-intake 
curve (Flaisher-Grinberg et al., 2009) and based on previous work 
done with BS mice (Hiscock et al., 2007). The saccharin solution 
bottle was available to the mice throughout the entire sweet solu-
tion preference test period. Weights of saccharin solution and 
water bottles were taken at the beginning of the experiment and 
every 24 h thereafter. Sweet solution preference was calculated 
daily as the ratio of saccharin out of total liquid consumption. 
For Stage 1, saccharin preference was measured across 4 days 
and for Stage 2 it was measured across 2 days because it was 
demonstrated that differences between groups were established 
within the first 2 days.
Light/dark box. The light/dark box apparatus consisted of a wooden 
box, 60 × 40 × 45 cm, divided by a partition to 1/3 covered, black-
painted segment and 2/3 open, well lit, white-painted segment. Mice 
were placed in the light compartment with the partition slightly 
ajar to permit free transitions between compartments. Behavior was 
digitally recorded from above for a 5-min session and recordings 
served to manually score the time spent in the light compartment. 
An entry into the light compartment was scored when all four paws 
the prototypic mood stabilizers valproate and lithium, and of the 
tricyclic antidepressant imipramine, on the behavior of BS mice 
were evaluated. Given that pharmacological validity is supported 
when drugs that are effective in the disorder (i.e., mood stabilizers 
such as lithium and valproate) are effective in the model while drugs 
that are not effective in the disorder (i.e., prototypic antidepressant 
such as imipramine) are not effective in the model (Willner, 1991) 
and in accordance with their effects in manic patients (Miklowitz 
and Johnson, 2006), it was hypothesized that valproate and lithium, 
but not imipramine, would induce an anti-manic effect.
matErIals and mEthods
subjEcts
For Stage 1, Black Swiss (Taconic, NY, USA), C57Bl/6 (Harlan, IN, 
USA), CBA/J and A/J (Jackson laboratory, ME, USA) mice were 
used. The selection of these strains was based on previous results 
in the amphetamine-induced hyperactivity model (Monleon et al., 
1995; Agmo et al., 1997; Anjaneyulu et al., 2003; Arban et al., 2005; 
Gould et al., 2007; Hiscock et al., 2007) and on previous experi-
ments performed in our laboratory. For Stage 2, only BS mice were 
utilized. All mice were transported to our laboratory, where experi-
mentation started no less than 1 week later to allow for appropriate 
acclimatization time. Male mice, 10 to 12 weeks old and 25 ± 7 g at 
the start of treatment period, were singly housed in a colony room 
with constant temperature (22 ± 1°C), 12/12 light dark cycle (lights 
on/off at 0730/1930) and ad-lib food and water. For the resident-
intruder test (see Behavioral tests), strain-matched mice served as 
intruders. Intruders were 7 to 8 weeks old, 22 ± 5 g at the start of 
treatment period and were group housed 3–4 in a cage under the 
same conditions as described above. All experiments were con-
ducted during the early light phase of the light/dark cycle, in dedi-
cated experimental rooms and under standard fluorescent lights 
(except for the sweet solution preference test, conducted in the col-
ony room). All experimental procedures followed NIH guidelines 
and were approved by the University of Minnesota Institutional 
Animal Care and Use Committee (Protocol No. 0610A94146). The 
number of animals per group in all experiments was 10–16 except 
for the amphetamine experiments where group size was half of the 
original number. Intruder mice were used twice and care was taken 
to counterbalance first and second exposures across test groups.
drugs and drug admInIstratIon
Valproate, lithium and imipramine (SIGMA, St. Lewis, MI, USA) 
were dissolved in saline to a dose of 50, 100 and 200 mg/kg (val-
proate), 100 and 200 mg/kg (lithium) or 10, 20 and 30 mg/kg (imi-
pramine) and administered via I.P. injection in a volume of 10 ml/  kg. 
Administration started 1 day before the beginning of the test battery 
and continued throughout the days of testing. Drugs were admin-
istered twice daily, with morning injections 30 min before testing 
and evening injections at 8 PM. For the amphetamine-induced 
hyperactivity test, d-amphetamine (SIGMA, St. Lewis, MI, USA) 
was dissolved in saline to a dose of 1 mg/kg and administered via 
I.P. injection in a volume of 10 ml/kg immediately before the begin-
ning of the test. Vehicle groups received an equivalent volume of 
saline. Drug doses were chosen based on their effects in animal 
models of affective disorders (e.g. Monleon et al., 1995; Agmo et al., 
1996; Gould et al., 2007) and in studies performed in our laboratory www.frontiersin.org  April 2010  | Volume 1  | Article 10  |  3
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main or interaction effects were followed by Fisher LSD post hoc 
comparisons. Significance was assumed at p < 0.05. For Stage 2 of 
the study, similar statistics were used except that the main factor in 
the different ANOVA tests was Drug dose (valproate 0, 50, 100, 200/
lithium 0, 100, 200/imipramine 0, 10, 20, 30) instead of strain.
rEsults
stagE 1: straIn dIffErEncEs In a battEry of modEls for manIa
As previously reported (for details see Flaisher-Grinberg et al., 
2009), BS mice demonstrated a significantly higher sweet solu-
tion preference compared with all other strains and across all 
4 days of the test (ANOVA: Strain, F(3,44) = 22.93, p < 0.0001, 
Day, F(3,132) = 42.63, p < 0.0001, Strain × Day, F(9,132) = 4.11, 
p < 0.001). As shown in Table 1, in comparison with the other 
strains, BS mice exhibited the highest level of aggression in the 
resident-intruder test, the lowest immobility time in the FST, the 
highest amount of time in the light compartment of the light/dark 
box (except for the CBA/J strain) and the most intense response 
to amphetamine. In the spontaneous activity test, both BS and 
C57Bl/6  mice  demonstrated  similar  activity  levels  which  were 
higher compared with A/J and CBA/J mice.
stagE 2: thE EffEcts of valproatE, lIthIum and ImIpramInE on thE 
bEhavIor of bs mIcE tEstEd In a battEry of modEls for manIa
Experiment 1: The effects of valproate in a battery of models for mania
As previously demonstrated (Flaisher-Grinberg and Einat, 2009b), 
200 mg/kg valproate reduced sweet solution preference across the 
2 days of the test and 100 mg/kg valproate reduced sweet solution 
preference on Day 1 with a similar trend on Day 2 (Figure 1A, Dose, 
F(3,36) = 9.98, p < 0.0001, Day, F(1,36) = 4.01, p < 0.05, Dose × Day 
interaction, F(3,36) = 0.65, p = 0.58, see Figure for results of post hoc 
comparisons). This effect was found despite the general increase in 
total liquid consumption following valproate administration (data 
not shown). As expected (Flaisher-Grinberg et al., 2009), 200 mg/kg 
valproate increased immobility time in the FST with a similar trend 
at the 100 mg/kg dose (Figure 1B, Dose, F(3,34) = 3.16, p < 0.05, see 
Figure for results of post hoc comparisons). In the amphetamine-
induced hyperactivity test, a trend for valproate-induced attenuation 
of amphetamine-induced hyperactivity was demonstrated, result-
ing from an attenuation at the 200 mg/kg dose (Figure 1C, Dose, 
F(3,30) = 2.66, p = 0.06, Stimulant, F(1,30) = 38.34, p < 0.0001, 
Dose × Stimulant interaction, F(3,30) = 2.04, p = 0.13, see Figure 
for results of post hoc comparisons). Valproate had no effect in the 
non-amphetamine treated groups.
Valproate had no effect on spontaneous activity across the entire 
session (F(3,35) = 1.63 p = 0.20) and across the first 10-min session 
(F(3,35) = 0.04 p = 0.98). Valproate also had no effects on behavior 
in the light/dark box (F(3,36) = 0.06, p = 0.97) or the resident-
  intruder test (F(3,36) = 1.84, p = 1.57). Interestingly, in contrast 
with the results of Stage 1, mice from the vehicle group demon-
strated a very low aggression ratio (mean = 0.25, SE = 0.06) in the 
resident-intruder test. N = 10/group in each of these three tests.
Experiment 2: The effects of lithium in a battery of models for mania
As  previously  demonstrated  (Flaisher-Grinberg  et  al.,  2009), 
200 mg/kg lithium reduced sweet solution preference across the 
2 days of the test (Figure 2A, Dose, F(2,44) = 8.14, p = 0.001, Day, 
of the mouse were in that compartment. At the end of the session 
mice were returned to their home cages and the area was wiped 
clean with a 10% alcohol solution.
Resident-intruder test. Resident mice were transferred in their 
home cages to an experimental room where cage covers were 
removed. After a 5-min adaptation period, a younger, previously 
group-housed mouse (i.e., intruder), was placed into the resident’s 
cage and behavior was digitally recorded from above for a 10-min 
session. Recordings served to manually score resident’s aggressive 
interactions (defined as attempts to bite, actual bite, boxing postures 
and wrestling postures) and non-aggressive interactions (defined as 
other types of body contact including sniffing, allogrooming and 
body contact). Behaviors performed when not interacting were not 
scored. The resident’s aggression score was calculated as the ratio 
of aggressive interactions out of total (aggressive + non-aggressive) 
interactions. At the end of the session the intruder was removed 
and placed back in its home cage, the resident’s cage was covered 
and both mice were returned to the colony room. To minimize 
harm to animals, mice were briefly separated when attacks became 
vicious and included significant biting. Hence, the total time of 
attacks could not be scored and only numbers of aggressive and non 
aggressive interactions were scored from recordings. This method 
was previously shown to be sensitive enough to demonstrate the 
effects of mood stabilizers in this test (Einat, 2007b).
Forced swim test (FST). Mice were placed for a 6-min session in a 
vertical cylindrical plastic container (25 cm tall × 18 cm diameter), 
filled to a depth of 15 ± 1 cm with tap water at 22 ± 1°C. This depth 
was sufficient to ensure that mice could not escape or touch the floor 
of the container. At the end of the session, mice were removed from 
the water, dried with a paper towel, and placed back in their home 
cage. Water in the container was changed after each session. Sessions 
were digitally recorded from the side and the last 4 min of each session 
were scored using an automated acquisition and analysis software 
(Biobserve, Bonn, Germany). Due to technical problems, sessions 
from Experiment 3, Stage 2, were manually scored by a trained experi-
menter, blind to the experimental conditions. Scored behaviors were 
defined as active (swim and struggle) versus passive (floating with only 
minimal movements needed to keep head above water) behaviors.
Amphetamine-induced hyperactivity. Mice were administered with 
amphetamine or vehicle and immediately placed in activity monitors 
for a 60-min session, where activity was detected by infrared beams 
and total ambulatory activity was calculated across the entire session. 
At the end of the session mice were returned to their home cages and 
the boxes were wiped clean with a 10% alcohol solution.
statIstIcal analysIs
For Stage 1 of the study, the spontaneous activity, light/dark box, 
resident-intruder and FST data were analyzed using analyses of 
variance (ANOVA) with Strain (BS/C57Bl/6/CBA/J/A/J) as a main 
factor. For the sweet solution preference test, data were analyzed 
using mixed ANOVA with Strain as a main factor and Day as a 
repeated measures factor. For the amphetamine-induced hyperac-
tivity test, data were analyzed using a two way ANOVA with Strain 
and Stimulant (amphetamine/vehicle) as main factors. Significant Frontiers in Psychiatry  |  Psychopharmacology    April 2010  | Volume 1  | Article 10  |  4
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experiment were scored manually. Previous pilots conducted in our 
laboratory demonstrated no differences between manual and auto-
mated scores (data not shown). Moreover, the scores of the control-
treated group in this experiment are comparable with the scores of 
the control-treated groups in Experiments 1 (see Figure 1B) and 2 
(see Figure 2B) of this stage.
dIscussIon
The need to develop more efficient and predictive methods of 
modeling BPD had been repeatedly emphasized. The present study 
supports the utility of Black Swiss mice as an appropriate strain to 
model a number of behavioral domains of the manic pole of BPD. 
Specifically, the results demonstrate that BS mice show a unique 
manic-like baseline behavioral pattern and a uniqe response to 
mood stabilizing drugs compared with other strains. BS mice show 
a number of ‘manic-like’ behaviors including increased reward-
seeking, risk-taking, aggressive, vigor and goal directed behaviors, 
as well as intense respone to amphetamine. Moreover, in BS mice, 
most of these behaviors are ameliorated by the prototypic mood 
stabilizers valproate and lithium but are not affected by the tryci-
clic antidepressant imipramine (Table 3), further supporting the 
relevance of the model to the human syndrom.
Identifying an appropriate model animal, species or strain for the 
purposes of modeling a specific disorder is an acknowledged and 
successful method of research. For instance, the Flinders Sensitive 
F(1,44) = 0.97, p = 0.32, Dose × Day, F(2,44) = 0.28, p = 0.75, see 
Figure for results of post hoc comparisons). No lithium effect on 
total liquid consumption was found in this test (data not shown, 
Dose, F(2,44) = 0.42, p = 0.65, Day, F(1,44) = 76.77, p < 0.0001, 
Dose × Day, F(2,44) = 2.13, p = 0.13). Lithium had no effect on 
spontaneous activity across the entire session (Dose, F(2,45) = 0.24 
p  =  0.78,  N  =  16/group)  and  across  the  first  10-min  session 
(Dose, F(2,45) = 0.08 p = 0.92) but it attenuated amphetamine-
induced hyperactivity at the 200 mg/kg dose without affecting 
the activity of non-amphetamine treated mice (Figure 2C, Dose, 
F(2,42) = 12.02, p < 0.0001, Stimulant, F(1,42) = 52.20, p < 0.00001, 
Dose × Stimulant interaction, F(2,42) = 4.05, p < 0.05, see Figure 
for results of post hoc comparisons). Lithium had no effects in the 
FST (Figure 2B, Dose, F(2,21) = 0.06, p = 0.93), the light/dark box 
(Dose, F(2,45) = 0.60, p = 0.55, N = 16/group) or the resident-
intruder test (Dose, F(2,43) = 1.44, p = 0.24, N = 16/group). Vehicle-
treated mice demonstrated a relatively low aggression rate in this 
last test (mean = 0.46, SE = 0.06).
Experiment 3: The effects of imipramine in a battery of models for mania
Imipramine administration did not induce any behavioral changes 
in the test battery for BS mice (Table 2). No imipramine effect on 
total liquid consumption in the sweet solution preference test was 
found (data not shown). As mentioned in the Section “Materials 
and Methods”, due to technical problems the FST results in this 
Table 1 | Strain differences in tests for domains of mania.
Test Measurement  Strain  N  Mean score ± SE  ANOVA analysis  
collected
Resident- intruder test 
(Ratio of aggressive/total 
interactions)
BS
C57Bl/6
CBA/J
A/J
11
12
12
12
0.72 ± 0.05 
0.29 ± 0.19*
0.03 ± 0.03*
0.30 ± 0.06*
Strain: F(3,43) = 15.37 , p < 0.0001. 1 BS 
mouse was excluded showing unusual 
circling behavior
Forced swim test: 
(Immobility time – sec)
BS
C57Bl/6
CBA/J
A/J
12
12
11
12
1.20 ± 0.44
125.57 ± 10.58*
33.44 ± 6.30*
167 .99 ± 5.02*
Strain: F(3,43) = 137 .32, p < 0.0001. 1 CBA/J 
mouse was excluded as an outlier (more than 
2xSTD from mean)
Light/Dark box: (Time in 
light Compartment – sec)
BS
C57Bl/6
CBA/J
A/J
11
12
12
12
152.82 ± 5.89
111.25 ± 9.82*
143.66 ± 26.17
 87 .66 ± 22.32*
Strain: F(3,43) = 5.17 , p < 0.01. 1 BS mouse 
was excluded because of camera malfunction
Amphetamine-Induced 
hyperactivity: (Total 
ambulatory activity)
Saline Amph Strain: F(3,36) = 14.98, p < 0.0001. Stimulant: 
F(1,36) = 35.98, p < 0.001. Interaction: 
F(3,36) = 6.16, p < 0.01. 1 C57Bl/6-vehicle 
mouse was excluded because of computer 
malfunction, 1 mouse from BS, C57Bl/6 and 
A/J groups were excluded as statistical 
outliers; 
BS 
C57Bl/6
CBA/J
A/J
5,6
5,5
6,6
6,5
3697 .20 ± 481.96
2774.60 ± 346.87
1173.67 ± 171.51
 526.33 ± 58.32
15953.67 ± 2871.14#
8500.80 ± 826.44#, *
6552.50 ± 1910.41#, *
836.00 ± 430.14*
Spontaneous activity: 
(Total ambulatory activity)
BS
C57Bl/6
CBA/J
A/J
9
10
9
9
4347 .33 ± 622.57
4235.90 ± 400.87
1426.55 ± 109.64*
1486.77 ± 376.43*
Strain: F(3,33) = 15.27 , p < 0.0001. Three BS, 
CBA/J and A/J mice and two C57Bl/6 mice 
were excluded because of computer 
malfunction
*Represents significant difference from BS mice (p < 0.05). #Represents significant difference between amphetamine- and vehicle-treated group within each strain 
(p < 0.05).www.frontiersin.org  April 2010  | Volume 1  | Article 10  |  5
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2007; Hiscock et al., 2007; Ashkenazy et al., 2008; Flaisher-Grinberg 
and Einat, 2009b; Flaisher-Grinberg et al., 2009) as well as species-
specific behaviors of non-treaditional model animals (Smale et al., 
2005; Einat, 2007a). Comparison between different strains or dif-
ferent species can provid a strong tool to explore the undelying 
mechanism of behavior (Smale et al., 2005).
The results of Stage 1 of this study, demonstrating that BS mice 
show ‘manic-like’ behaviors compared with other strains, com-
bined with the results of Stage 2 showing that these behaviors are 
attenuated by mood stabilizers but not by antidepressant treatment, 
provide face and pharmacological validity to the use of this strain 
in a specific battery of tests for mania. Moreover, the drug response 
profile demonstrated by BS mice in the current study is unique as it 
demonstrate ‘anti-manic’ effects in tests traditionaly used to asess 
the effects of depressenogenic manipulation and antidepressant 
drugs (see discussion below). The differences between the strains 
and the differences in drug effects can be utilized to (1) select an 
appropriate strain for modeling purposes (2) explore the relevance 
of these behavioral phenotypes to the underlying biology of the 
different strains and (3) screen for new and improved mood sta-
bilizing/anti-manic drugs. It is important to note, however, that 
the findings demonstrating ‘manic-like’ behavioral phenotype in 
BS mice do not imply that these mice are “manic” as there is no 
evidence at this time that their behavior has identical causative 
rats line has been used as a model for depression (Overstreet, 1986) 
and the Alcohol Preferring P rats have been used as a model for 
alcoholism (Penn et al., 1978). Lewis rats have been used to study 
the biological mechanisms underlying obsessive compulsive dis-
order (Brimberg et al., 2007) and Fischer 344 and Lewis rats have 
been used to study susceptibility to psychoactive drugs and to stress 
(Suzuki et al., 1988; Cohen et al., 2006). Strain differences have been 
suggested as a method to define predictive responses to current 
medications (Porsolt et al., 1978; Gould et al., 2007) and to select 
appropriate animals for behavioral models of specific disorders and 
as background for the development of animal with targeted muta-
tions (Crawley, 1999; Gould et al., 2007). In the field of BPD and 
mania modeling, recent studies identified a number of mice strains 
with targeted mutations that demonstrate a variety of ‘manic-like’ 
behaviors, including mice with targeted mutations of the Clock 
gene (Roybal et al., 2007), dopamine transporter (Ralph-Williams 
et al., 2003), and glutamate receptors (Shaltiel et al., 2008) (see 
Malkesman et al., 2009 for review). The development of model 
animals through targeted mutations has a number of advantages 
as they directly indicate possible mechanisms related to the under-
lying biology of the disorder (Malkesman et al., 2009). However, 
considering the conceptual and practical problems associated with 
models based on targeted mutations, there are also advantages in 
studying the neural basis of strain-specific behaviors (Gould et al., 
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FIguRE 1 | Mean and standard error of (A) saccharin preference ratio on 
days 1 and 2 of the sweet solution preference test (B) immobility time (s) 
in the FST of BS mice treated with valproate and (C) total activity of BS 
mice treated with valproate and amphetamine. *Significantly different 
from the vehicle group (p < 0.05). N = 10/group for (A,B), N = 5/group for 
(C), except for the following: FST; 1 mouse from the 50 mg/kg and 1 mouse 
from the 100 mg/kg group, amphetamine-induced hyperactivity; 1 mouse 
from the 50 mg/kg + vehicle group and 1 mouse from the 200 mg/
kg + amphetamine group were excluded from analysis due to automated 
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lithium reduced amphetamine hyperactivity (Borison et al., 1978). 
Adminsitration of 200 mg/kg lithium reduced aggression in mice 
(Nakao et al., 1985) and lithium at 100 mg/kg and valproate at 
200 mg/kg attenuated neuropeptide S-induced hyperactivity (Castro 
et al., 2009). Because specific drug levels in plasma or brain were 
not assessed in the present study the possibility that other doses 
and dosing regimens might have different effect profiles is left open. 
However, the similarities between drug doses in this and in previous 
studies support the relevance of the current findings. Moreover, it is 
also possible that even when plasma levels are monitored, the infor-
mation is not enough to make clear extrapolations to the human 
conditions. First, the metabolism of mice is different than that of 
humans and therefore the kinetics of drugs is also different. For 
example, whereas the standard dose of imipramine for the treat-
ment of depression is 1–4 mg/kg per day (e.g. Leucht et al., 2000), 
doses used in animal experimentation range between 10 and 30 mg/
kg per day (e.g. Einat et al., 1999). Additionally, the presence of the 
drug in the plasma is not always a representation of its presence in 
the brain (e.g. Kovacsics and Gould, 2009).
Some of the drug effects in the present study might seem to 
be in contrast with prior reports. All three drugs were previously 
found  to  increase  sweet  solution  preference  [lithium  (Orsetti 
et al., 2006) valproate (Monleon et al., 1995; Papp et al., 1996) 
imipramine (Papp et al., 1996)]. However, these ‘antidepressant-
like’ effects were found in animals which were previously exposed 
  factors or general symptomology with the disorder. Moreover, these 
findings do not contradict the possibility that other mice strains 
might also demonstrate ‘manic-like’ behaviors in these and other 
relevant tests. Importantly, an investigation of the biochemical 
and molecular underpinning of the unique set of behaviors dem-
onstrated by BS mice in comparison to other strains is currently 
performed in our laboratory. A specific emphasis is being placed 
on molecular pathways which were previously implicated in mania 
and/or BPD or its treatment [PKC (Einat et al., 2004, 2007), GSK-3 
(Gould et al., 2006), BCL-2 (Lien et al., 2008; Chang et al., 2009) 
and BDNF (Frey et al., 2006a)].
In the current study it was also demonstrated that the profiles of 
the effects of lithium and valproate were not identical (see Table 3). 
Whereas this may seem to question the relevance of the results to the 
human syndrome, it is suggested that the varied effects in the model 
are not different than the variability of effects of mood stabilizers in 
patients (Cousins and Young, 2007). In fact, the differences between 
the specific effects of lithium and valproate across the test battery 
suggests a way to distinguish the effects of treatment on separate 
domains of the disorder (Einat, 2007a). It is however also possible 
that some of the differences in effects are related to drug levels in 
the brain. In the present study, drug doses were chosen based on 
their effects in animal models of affective disorders. For example, 
100 and 200 mg/kg lithium increased the threshold for rewarding 
intracranial self stimulation (Mavrikaki et al., 2009), 50 mg/kg of 
12
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FIguRE 2 | Mean and standard error of (A) saccharin preference on days 1 
and 2 of the sweet solution preference test (B) immobility time (s) in the 
FST of BS mice treated with lithium and (C) total activity of BS mice 
treated with lithium and amphetamine. *Significantly different from the 
vehicle group (p < 0.05); #difference between amphetamine groups. N = 16/
group for (A), N = 14/group for (B), N = 8/group for (C). In the FST, the results of 
2 mice from each group were excluded from the statistical analysis due to a 
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Table 3 | The domains of ‘manic-like’ behavior modeled in the battery, the expected response and actual response to mood stabilizers in BS mice.
Test Domain of manic-like 
behavior 
Expected response to 
mood stabilizers
Actual response to 
lithium
Actual response to valproate
Sweet solution preference Reward seeking behavior  Reduction in preference Reduction in preference Reduction in preference
Forced swim test Resistance to despair/
increased vigor
Increase in immobility No effect Increase in immobility
Resident-intruder test Aggression Reduced aggression No effect No effect
Dark/light box Risk taking behavior Reduced time in light 
Compartment
No effect No effect
Amphetamine-induced 
hyperactivity
Manic-like increased 
activity or sensitivity to 
psychostimulants
Reduced hyperactivity Reduced hyperactivity Reduced hyperactivity (strong 
trend)
Table 2 | Behavioral effects of imipramine administration in tests for domains of mania.
Test measures collected  Imipramine dose  N  Mean ± SE  Statistical analysis
Spontaneous activity 
(Total ambulatory activity)
Control
10 mg/kg
20 mg/kg
30 mg/kg
12
12
12
11
3806 ± 439
3458 ± 532
3216 ± 446
3439 ± 266
F(3,44) = 0.32, p = 0.81
Sweet solution preference 
(ratio of saccharin 
consumption to total liquid 
consumption)
Control
10 mg/kg
20 mg/kg
30 mg/kg
12
12
12
11
Day 1: 0.61 ± 0.03
Day 2: 0.56 ± 0.02
Day 1: 0.59 ± 0.03
Day 2: 0.59 ± 0.02
Day 1: 0.59 ± 0.03
Day 2: 0.52 ± 0.02
Day 1: 0.55 ± 0.03
Day 2: 0.54 ± 0.02
Imipramine: F(3,43) = 1.96, p = 0.14;
Day: F(1,43) = 1.83, p = 0.18; Interaction: 
F(3,43) = 0.85, p = 0.48
Forced swim test 
(immobility time – sec)
Control
10 mg/kg
20 mg/kg
30 mg/kg
11
12
12
10
60.4 ± 10.6
67 .9 ± 12.4
54.2 ± 10.9
41.5 ± 9.3
F(3,42) = 1.03, p = 0.39. 1 mouse from 
control and 1 from 30 mg group were 
excluded because of computer 
malfunction
Light/dark box (Time in 
light compartment – sec)
Control
10 mg/kg
20 mg/kg
30 mg/kg
12
12
11
11
163 ± 2.7
160 ± 5.0
154 ± 9.5
155 ± 5.9
F(3,43) = 0.38, p = 0.77 . 1 mouse from 
the 20 mg group was excluded as a 
statistical outlier (2xSTD away from 
mean)
Resident-intruder test 
(Ratio of aggressive/total 
interactions)
Control
10 mg/kg
20 mg/kg
30 mg/kg
11
11
12
10
0.43 ± 0.07
0.36 ± 0.09
0.37 ± 0.09
0.35 ± 0.08
F(3,40) = 0.2, p = 0.89. 1 mouse from 
control group, 1 from 10 mg group and 1 
from 30 mg group were excluded due to 
computer malfunction
Amphetamine-induced 
hyperactivity (Total 
ambulatory activity)
Control Vehicle Amph Imipramine: F(3,38) = 1.85, p = 0.15. 
Amphetamine: F(1,38) = 51.99, 
p < 0.001. Interaction: F(3,38) = 1.96, 
p = 0.14. 1 mouse from the 
control + vehicle group was excluded 
because of computer malfunction
5,6
6,6
6,6
6,5
2254 ± 254
2658 ± 354
1802 ± 363
2294 ± 281
5308 ± 1092
9251 ± 1822
9374 ± 1318
6517 ± 1435
10 mg/kg
20 mg/kg
30 mg/kg
to depressenogenic   stimuli while in the present study BS mice were 
found to   demonstrate excessive baseline sweet solution preference 
which was suggested to represent strain-specific, ‘manic-like’ high 
reward-seeking behavior (Flaisher-Grinberg et al., 2009). Therefore, 
the reduction in sweet solution preference induced by valproate 
and lithium in the current study are in line with the hypothesis 
and are assumed to represent an anti-manic, rather than an anti-
depressant effect (see Table 3). A similar idea can be demonstrated 
regarding drugs effect in the FST. In the present study, valproate was 
shown to increase immobility time in the FST whereas   previous Frontiers in Psychiatry  |  Psychopharmacology    April 2010  | Volume 1  | Article 10  |  8
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preference for one compartment over the other (baseline behavior 
is at the range of 150–160 s out of 300-s session, showing lack of 
preference for either of the compartments and hence, no anxiety-
like behavior). Since imipramine is expected to reduce anxiety (de 
Angelis, 1996), the lack of anxiety demonstrated by BS mice in this 
test might account for its lack of effect.
In the current study, several rodent tests have been proposed as 
models for some of the domains of mania and the effects of two 
mood stabilizers and one antidepressant drug in these tests were 
assessed. However, the spectrum of behaviors demonstrated in the 
present study is limited compared with the spectrum of mania 
and additional tests should be devised that might model further 
domains of the disorder such as reduced sleep, increased sexual 
drive and abuse of drugs (Einat, 2007a).
The testing of mice in a continuous set of tests demands a number 
of important considerations. First, although in the current study 
tests were arranged from less to more intrusive, it is possible that 
some tests are more susceptible to previous stress than others (see 
above for the resident-intruder and light/dark box). Another con-
sideration deals with continuous drug administration. Given that 
tests are conducted sequentially, this factor introduces variability in 
the time course of drug treatment at the time of the different tests. 
Although the effects of acute treatment are not always comparable 
with the effects of sub-chronic or chronic treatments, this factor 
might be overcome by starting treatments a few days prior to the 
behavioral testing. Importantly, most mood stabilizers are expected 
to have more pronounced effects after chronic treatment compared 
with acute treatment (Kovacsics and Gould, 2009), whereas other 
drugs may have effects that tolerate across time. Finally, the inclu-
sion of the amphetamine-induced hyperactivity test in the battery 
imposes the use of a smaller number of mice in each group in this 
test. Specifically, in the amphetamine-induced hyperactivity test, 
half the mice assigned to each treatment group in the other tests 
are treated with amphetamine and half are treated with vehicle. 
Although in the current study the number of animal per group in 
the amphetamine-induced hyperactivity tests ranges from 5 to 8, 
the findings that lithium and valproate attenuate amphetamine-
induced hyperactivity, while imipramine has no effect, are in line 
with previous reports in rodents [e.g., lithium: (Frey et al., 2006b; 
Gould et al., 2007; Kim et al., 2008) imipramine: (Dziedzicka-
Wasylewska et al., 1997)]. Future experiments will validate these 
results using a higher number of mice per group.
A different consideration involves timing of testing within the 
light/dark cycle of the animals. It may seem appropriate to test 
nocturnal animals during their dark (and not light) phase in a way 
that will have higher homology with the active phase of diurnal 
humans. However, the dark phase of nocturnal animals is not the 
exact reversal of the light phase in diurnal animals as the biology 
of circadian rhythms is more complicated. For example, although 
the main circadian hormone melatonin is secreted during the dark 
in both diurnal and nocturnal mammals, nocturnal mammals are 
active when melatonin levels are high, while diurnal mammals are 
active when melatonin levels are low (Challet, 2007). As such, it is 
possible that regardless of the time of testing, a full homology of 
the circadian phase between nocturnal mice and diurnal humans 
is not attainable. Given that the current study did not evaluated the 
possible effects of light/dark phase on the demonstrated behavioral 
studies found that all the drugs used in the present study decrease 
immobility in the test [lithium (Bersudsky et al., 2007; Gould et al., 
2008), valproate (Bourin et al., 1996; Kulkarni and Dhir, 2007), 
imipramine (Porsolt et al., 1978)]. Importantly, these ‘antidepres-
sant-like’ effects of both mood stabilizers and antidepressant drugs 
were demonstrated in studies in which rodent strains with high 
baseline immobility were used [C57Bl/6 and NIH-Swiss (Bourin 
et al., 1996), Swiss mice (Porsolt et al., 1978), CD, NMRI and OF-1 
(Porsolt et al., 1978; Swiergiel et al., 2007)]. In the present study, 
BS mice were found to show low baseline immobility in the FST, 
a behavior which was suggested to represent ‘manic-like’ exces-
sive vigor and goal directed activity (Roybal et al., 2007; Flaisher-
Grinberg and Einat, 2009b). It is therefore reasonable to expect 
that in these mice the effects of mood stabilizers would be to act 
as anti-manic, i.e. increase immobility time [valproate (Flaisher-
Grinberg and Einat, 2009b); current study; lithium, and a number 
of mutant mice models (Roybal et al., 2007; Engel et al., 2008)]. In 
contrast, while imipramine is known to reduce immobility time in 
many strains, it is suggested that its lack of effect in BS mice in the 
current study reflect a floor effect, due to the low immobility levels 
demonstrated by BS mice. Although it is possible that different 
imipramine doses would have produced an effect, this possibility 
seems less likely given that the doses used in the study were previ-
ously demonstrated to have effects in different mice strains.
In the context of the current results, it is important to note that 
the spontaneous locomotor activity of BS mice was not affected 
by any of the drugs and therefore it is reasonable to suggest that 
the effects of the mood stabilizers were not related to a generalized 
change in activity but are specific to the tests. This is in contrast 
to strains such as FVB/NJ mice or some mice strains with targeted 
mutations (such as the ERK1 heterozygote mice), which were found 
to show low immobility in the FST combined with generalized 
hyperactivity (Engel et al., 2008; Milner and Crabbe, 2008), sug-
gesting a generalized, non specific behavioral change.
In the present study it was hypothesized that valproate and 
lithium would induce an anti-manic reduction in the risk-taking 
and aggressiveness demonstrated by BS mice. The lack of drug 
effect in the light/dark box and the resident-intruder test are in 
contrast with these hypothesis as well as with previous reports 
demonstrating anxiolytic effects [imipramine (de Angelis, 1992, 
1995); valproate (Yoshimura and Ogawa, 1984; Ibarguen-Vargas 
et al., 2009)] and anti-aggressive effects [imipramine (Pinna et al., 
2004); valproate (Einat, 2007b); lithium (Wei et al., 2007; Uchida 
et al., 2009; Veenema, 2009; Veenema and Neumann, 2009)] in these 
tests. The lack of effects in the resident-intruder test could be at least 
partially explained by the low baseline aggression found in Stage 2 
of the present study, which could have created a floor effect masking 
possible drug effects. It is also possible that the previous exposure of 
mice to a variety of stressors across the test battery had a significant 
influence on their behavior, as stress was shown to alter aggressive 
behavior in mice (e.g., Uchida et al., 2009). In the context of the 
current study, saccharin deprivation following the establishment of 
saccharin preference (a possible consequence of the sweet solution 
preference test, conducted before the resident-intruder test) has 
been found to influence rodents’ aggressive behaviors (Belozertseva 
et al., 2004). The lack of effect of imipramine in the light/dark box 
might be explained by the fact that in this test BS mice show no www.frontiersin.org  April 2010  | Volume 1  | Article 10  |  9
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